Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; tryptophan, quantity: 1.9 g/l; methionine, quantity: 5.6 g/l; isoleucine, quantity: 5.6 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - acetate, quantity: 135 mmol/l; leucine, quantity: 5.9 g/l; valine, quantity: 5.5 g/l; arginine, quantity: 8.4 g/l; sulfate, quantity: 8 mmol/l; isoleucine, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; phenylalanine, quantity: 5.9 g/l; aspartic acid, quantity: 2.5 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; alanine, quantity: 12 g/l; chloride, quantity: 100 mmol/l; potassium, quantity: 50 mmol/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; threonine, quantity: 4.2 g/l; - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tryptophan, quantity: 1.9 g/l; arginine, quantity: 11.3 g/l; phenylalanine, quantity: 7.9 g/l; cysteine, quantity: 0.56 g/l; tyrosine, quantity: 0.23 g/l; glycine, quantity: 7.9 g/l; threonine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; alanine, quantity: 16 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); serine, quantity: 4.5 g/l; histidine, quantity: 6.8 g/l; proline, quantity: 6.8 - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; leucine, quantity: 5.9 g/l; tryptophan, quantity: 1.4 g/l; isoleucine, quantity: 4.2 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; histidine, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; valine, quantity: 5.5 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; methionine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; threonine, quantity: 4.2 g - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 12 g/l; glutamic acid, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; lysine hydrochloride, quantity: 8.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; tryptophan, quantity: 1.4 g/l; leucine, quantity: 5.9 g/l; potassium, quantity: 50 mmol/l; serine, quantity: 3.4 g/l; sulfate, quantity: 8 mmol/l; acetate, quantity: 135 mmol/l; methionine, quantity: 4.2 g/l; glycine, quantity: 5.9 g/l; cysteine hydrochloride, quantity: 0.61 g/l (equivalent: cysteine, qty 0.42 g - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); threonine, quantity: 4.2 g/l; proline, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; glutamic acid, quantity: 4.2 g/l; isoleucine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; methionine, quantity: 4.2 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; aspartic acid, quantity - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); glutamic acid, quantity: 5.6 g/l; threonine, quantity: 5.6 g/l; glycine, quantity: 7.9 g/l; aspartic acid, quantity: 3.4 g/l; tyrosine, quantity: 0.23 g/l; phenylalanine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; arginine, quantity: 11.3 g/l; alanine, quantity: 16 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; cysteine, quantity: 0.56 g/l; histidine, quantity: 6.8 g - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: sodium sulfate; sulfuric acid; sodium acetate trihydrate; water for injections - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetate trihydrate; sodium sulfate; sulfuric acid - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 200 mg/ml - injection, emulsion - excipient ingredients: water for injections; egg lecithin; sodium hydroxide; glycerol - parenteral nutrition for patients when oral or enteral nutrition is impossible or insufficient or contraindicated.